Through the combination of GeneDx’s industry leading proprietary dataset, publicly available data, and the power of AI, Multiscore prioritizes genes with positive findings in exome and genome ...
Through the combination of GeneDx’s industry leading proprietary dataset, publicly available data, and the power of AI, Multiscore prioritizes genes in exome and genome sequences by ranking them ...
Multiscore, a Gene Ranker Powered by Artificial Intelligence and Real-World Clinical Data, Shows High Sensitivity in 10,000 Exomes and Genomes will be presented by Vinnie Ustach, PhD (GeneDx) on ...
GeneDx Holdings Corp. (NASDAQ:WGS) Receives Consensus Recommendation of “Moderate Buy” from Analysts
GeneDx (NASDAQ:WGS – Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66.
In this article, we are going to take a look at where GeneDx Holdings Corp. (NASDAQ:WGS) stands against other best multibagger stocks to buy in 2025. In the world of investing, the term ...
GeneDx Holdings Corp. (NASDAQ:WGS) delivered exceptional Q4 results with revenues exceeding $95 million and gross margins expanding to 70%. The company’s exome ... out our report about the ...
We recently published a list of 12 Best Multibagger Stocks to Buy in 2025. In this article, we are going to take a look at where GeneDx Holdings Corp. (NASDAQ:WGS) stands against other best ...
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback